Drugs / TetraVax-DV TV005
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02873260 | Aug 2016 → Nov 2017 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT02879266 | Feb 2016 → Sep 2017 | dengue disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TetraVax-DV TV005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02879266 ↗ |
| Modality | Vaccine | “live attenuated recombinant tetravalent dengue virus vaccine” NCT02873260 ↗ |
| Route | Subcutaneous | “TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.” NCT02873260 ↗ |